Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

Abstract

BackgroundEvidence-based randomized clinical trials have shown significant benefit of statin treatment with regard to cardiovascular disease. In anticipation of the National Cholesterol Education Program Adult Treatment Panel IV guidelines, we wanted to assess the current state of lipid goal attainment in the high-risk secondary prevention population in the United States. The objectives of the study were to estimate the proportion of high-risk patients treated with statin monotherapy who achieved Adult Treatment Panel III–recommended low-density lipoprotein cholesterol (LDL-C) goals (<100 mg/dL; optional <70 mg/dL) as well as non–high-density lipoprotein cholesterol goals (<130 mg/dL; optional <100 mg/dL).Methods and ResultsThis is a cross-sectional, retrospective study of 3 data sources: electronic medical records (2003–September 2010), administrative claims data (2003–2010), and National Health and Nutrition Examination Survey data (2007–2008). High-risk patients (≥18 years of age) were defined as those with a history of coronary heart disease or coronary heart disease risk equivalent who had the latest complete lipid panel measurement and had been treated with statin monotherapy for >90 days at the time of the lipid panel. Cardiovascular disease, coronary heart disease, and coronary heart disease risk equivalents were defined on the basis of availability, specific to each data source. Across the 3 data sources, 20% to 26% of high-risk patients treated with statin monotherapy for >90 days had LDL-C <70 mg/dL, and 67% to 77% had LDL-C <100 mg/dL. The percentages of those attaining both LDL-C goals and non–high-density lipoprotein cholesterol goals were quantitatively smaller (13.5% to 19.0% and 46% to 70%).ConclusionsAcross the 3 data sources, there was consistency in the proportion of high-risk patients treated with statin monotherapy who were at LDL-C goal. A significant number of these statin-treated patients had additional dyslipidemias.

Analysis of Hypercholesterolemia Prevalence in the Outpatient Practice (According to the Argo Study): Part I

“…Показано, что целевого уров-ня ХС ЛПНП<70 мг/дл достигли 20-26% пациентов c высоким сердечно-сосудистым риском, принимав-ших статины, а ХС ЛПНП<100 мг/дл -67-77% паци-ентов [18].…”

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

“…Nevertheless, some patients cannot tolerate recommended statin doses1; a high proportion of patients do not achieve adequate reduction of low‐density lipoprotein cholesterol (LDL‐C), despite high‐intensity statin therapy2; and even patients who achieve guideline recommended reductions may have high residual ASCVD risk 3. Consequently, alternative therapies designed to lower LDL‐C and improve outcomes are needed.…”

Improvement of Medical Care for the Patients With Lipid Disorders (Case of Lipid Center of the “District Cardiological Dispensary “Center for Diagnostics and Cardiovascular Surgery”, Surgut City)

“…По результатам исследования EUROASPIRE III, в котором принимали участие 22 страны (в том числе, Россия), даже у больных, перенесших острые коро-нарные осложнения и вмешательства по реваскуля-ризации миокарда, не достигается надлежащий контроль уровня холестерина, глюкозы, артериаль-ного давления, не корригируется психологическое состояние [2]. При проведении ретроспективного анализа данных электронных медицинских карт (2003-2010гг), результатов административных прове-рок (2003-2010гг), а также данных обследования в рамках Национального исследования здоровья и питания (2007-2008гг) в США было показано, что целевого уровня холестерина липопротеидов низкой плотности (ХС ЛНП) <100 мг/дл -67-77% пациен-тов, а ХС ЛНП <70 мг/дл достигли лишь 20-26% пациентов c высоким сердечно-сосудистым риском, принимавших статины [10].…”